Strong revenue growth masked by margin compression and guidance delays

Delivered ₹2,187 Cr implies Q1 FY26 base ~₹1,838 Cr; 19% confirmed by math

Delivered ₹2,545 Cr; implies Q1 FY26 was ~₹2,169 Cr; matches guidance math

Delivered PAT ₹272.8 Cr, not ₹263 Cr. Actual YoY growth only 2.3%, not 4%

Delivered OPM 21.5% aligns with this. Management ex-acquisitions states margin 'similar to Q1 FY26 at 22%'

Management acknowledges slower growth than peers; growth rate matches guidance

Q1 at 21.5%, target is +350 bps over 4 qtrs. Dependent on new unit ramp (+1% swing) and ESOP efficiency gains (~14% of EBITDA charge). Achievable but not confirmed

Prior FY26 call: 150-200 bps improvement to ~24% by FY27. Now: 25% by FY28, dependent on ESOP offset. Margin recovery delayed 4 quarters; contingent on new units ramping vs prior organic plan.

Prior: double-digit growth (implied 12%+). Current delivery: 10.2%. Management guides 12-13% rest of year but industry is 15%. New MD joining but no aggressive acceleration committed; relying on B2C mix shift (53% now, targeting 55-58%).

Prior: oncology high-growth specialty (23-24% YoY). Q1 FY27: 5% due to government chemo pricing cut (30% discount ECHS/CGHS). Management expects stabilization at 10-12%, not prior growth rate. Permanent margin drag ~100-150 bps.

2,000 bed brownfield plan on track. Q1 added 100 beds. FY27: 400 more planned (200 FMRI alone). Oncology fit-out (Manesar Nov, Faridabad/Amritsar starting) expected to unlock margin upside +1% over 12 months.

No major acquisitions announced. Management pursuing deals but won't disclose until concluded. Odisha O&M (300 beds) is learning play, no capex. Strategy unchanged: focus on existing clusters (Delhi NCR, Bangalore, Punjab, Mumbai, Kolkata).

Broad-based across all zones, not Delhi NCR only. 1.5 years of deliberation; strategic alignment of doctor interests with company performance, not reactionary. Doctors partner in efficiency (consumption control, profitability).

Margin guidance maintained. ESOP will contribute positively to operating performance through efficiency gains, offsetting cost. New units (FMRI, Manesar) and occupancy ramps provide additional levers.

Post-ESOP. Confidence high due to FMRI ready, Manesar ramping, multiple cost reduction initiatives. New units will contribute positively once stabilized.

Manesar: 187 beds operational (60% occupancy), oncology equipment Nov 2026; by year-end mid-teens margin expected. Noida: 8-10% month-on-month revenue growth, steady occupancy ramp; both facilities mid-teens to higher by year-end with talent acquisition.

New units swing from -0.4% drag to +1% contribution. New doctors settling in 4 units. Legal costs from Delhi High Court hearing are transient (not baseline). Provision for doubtful debt being plugged (government/TPA collections lagging). Occupancy leverage in BG Road & Mulund (historically low). FMRI and Manesar oncology will drive incremental margin.

100 beds done Q1. 400 beds remaining Q2-Q4. Major: FMRI 200 beds (occupancy certificate expected this month). Others on track across Noida, Amritsar, Jalandhar.

Q1 charge partial (from April 23). Q2-Q4 expected ~₹40 Cr/quarter if employee base stable. Year 2: ~₹30 Cr/quarter. Year 3: ~₹25 Cr/quarter.

No capital commitment in Odisha; O&M only (learning play). Strategy remains clusters: Bangalore, Delhi NCR, Punjab, Mumbai, Kolkata. Evaluating acquisitions in existing clusters. Odisha is option for future participation if O&M partner performs well.

Can't share specific numbers. General: significant improvement in operating margins across 5 facilities managed. New doctors, new teams. Margins moving positively but not yet Fortis standard; needs 2-4 quarters more stabilization.

New MD (10 days tenure) will rework plans. Strategy: focus on sustainable profitable B2C-led growth (stickier, higher margin) vs pure volume chase. B2C ratio rising 53-55-58% trajectory. Region-wise seeing good NCR growth; will replicate elsewhere. Will reach industry levels 'within next few quarters' (no specific date).

Chemo business driven by government pricing (30% discount on MRP for ECHS/CGHS). Oncology growth slowed from 23-24% to 5%. Will stabilize at 10-12%. Focusing on radiation therapy & surgical oncology to maintain comprehensive care. Not operational failure; regulatory headwind.

3% of revenue per O&M agreement. Q1 FY27: ₹6 Cr.

Blended 70% occupancy reflects new unit dilution (renovations in Bangalore, new acquisitions). Core 14 facilities at strong occupancy. Levers: Manesar, Yeshwanthpur, Greater Noida ramp-ups. BG Road (historically low) is major opportunity. Expected 2-3% occupancy point improvement going forward via talent acquisition and marketing.

FMRI at ~25% margin now. New beds will maintain and possibly improve margin. Initially some cost to add talent, but on larger base will preserve EBITDA %; upside possible as facility scales.

Growth phase: ~50% of EBITDA to brownfield expansion (2,000 bed plan). Also investing in proton, robotic surgery, advanced therapies. M&A: pursuing some deals but can't disclose until concluded. Deals focused on clusters.

55-60% of doctors and senior admin staff. Not only doctors. Proportion may vary by need. Attrition: Micro-market issue (Noida saw flutter when new hospitals opened). Supply of clinical talent improving significantly. Younger generation trained post medical college expansion 15y ago; won't be big problem going forward.

Under finalization. Capex ~₹252 Cr.

No call options in 2-3 current O&M hospitals. Gleneagles discussions with IHH ongoing on path forward.

Diagnostic revenue: 12-13% for rest of FY27. EBITDA margin: 24-25% range for remaining time. Preventive portfolio trending up (14% now vs 12%), specialized up (35% vs 34%). Momentum to continue.

Bed expansion (100 Q1, 400 FY27 planned) and ARPOB gains (+2.6% Y1) drive revenue. FY27 guidance not formally re-guided but trajectory clear from Q1 beat

Q1 delivered 10.2% vs 15% industry. New MD (Vijender Singh, 10 days in) guiding acceleration via B2C mix shift (53→55-58% target) and NCR regional replication. Timeline vague; '≈next few quarters' to match industry levels

Prior: 150-200 bps improvement to ~24% by FY27. Current: delayed to 25% by FY28. Dependent on new units ramp (+1% swing), ESOP efficiency offset (~₹40 Cr/qtr charge), occupancy improvement (2-3ppts), Manesar oncology Nov 2026. Multiple moving parts; execution risk.

Q1 delivered 23.9%; within guidance range. Portfolio mix shift (preventive +2%, specialized +1%) and B2C expansion support margin. Confidence high given immediate execution visible

FMRI 200 beds imminent. Manesar/Greater Noida/Yeshwanthpur ramping. Faridabad/Amritsar oncology starting. Plus: Proton (₹252 Cr), robotic surgery, advanced therapies investment

Chemo drug pricing cut (30% discount on MRP for ECHS/CGHS) slowed oncology from 23-24% to 5% growth. Similar intervention could affect other specialties. Pricing power compromised in government segments.

Provision for doubtful debt increased Q1 due to collection delays from government payor and TPA (Third Party Administrators). Impact on cash flow and working capital not quantified. Being worked on but no firm timeline to resolution.

Manesar, Greater Noida, Gleneagles, and acquisition facilities currently below 10-15% EBITDA margin. Timeline to reach 20%+ EBITDA uncertain. Manesar depends on Nov 2026 oncology equipment fit-out. Occupancy growth and clinical talent acquisition critical. Delay would push margin recovery timeline beyond FY28.

Agilus growing 10.2% vs 15% industry growth. New MD (Vijender Singh) just joined (10 days); track record at Agilus unproven. Promises acceleration but vague timeline ('next few quarters'). Brand stabilization and rebranding completed but competitive position weakening. Risk: continued market share loss if acceleration doesn't materialize.

₹40 Cr per quarter ESOP charge (~14% of quarterly EBITDA ≈ ~56-60 bps margin impact) starting Q2 FY27. Management maintaining 25% margin guidance assuming ESOP drives efficiency gains and cost reduction ('better profitability profile'). Offset unproven; if efficiency gains don't materialize, margin guidance would miss.